Abstract
Nanomedicine becomes a key player especially as next generation medicine. Antibody-conjugated nanomedicine could significantly upgrade the treatment and expand application areas. However, there are extensive challenges of manufacturing those formulations as a final drug product. Here we provided the general technical guidance from the initial formulation construction including antibody conjugation to the downstream formulation development. We hope this technical note can help accelerate the translation of productizing the antibody-conjugated nanomedicines.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call